Stereotaxis is trying to convert a twenty-year robotic electrophysiology franchise into a self-supplied catheter and digital-surgery platform after the Johnson and Johnson supply arrangement ended at year-end. The second-quarter print is the first real commercial test of that swap: proprietary MAGiC ablation catheters finally contribute meaningful disposable revenue, while system shipments stall because no Genesis robot left the dock. The investment debate is whether that catheter ramp, plus GenesisX and Synchrony, can fund cash-flow profitability in the first half of next year before the thin cash pile forces another equity raise.
The tension sits in the mix. Recurring revenue rose to $6.2 million as MAGiC and related disposables offset procedure pressure from the Johnson and Johnson exit. System revenue fell to $1.5 million because the quarter carried no robotic-system delivery, only early Synchrony cockpit sales. Gross margin held at 58 percent, but that print still embeds low manufacturing volumes at Osypka and a thin system margin. Cash ended June at $10.5 million with no funded debt. Quarterly free-cash-flow use stayed near $3.7 million. That mix tells investors the franchise is rotating toward disposables faster than systems can refill the top line.
The quarter's evidence is early and incomplete. About a dozen United States sites cleared hospital purchasing for MAGiC and started cases, and robotic-catheter revenue crossed $1 million after nearly tripling sequentially. Management guides recurring revenue toward $7 million then $8 million across the back half, and models cash-flow profitability in the first half of next year. The open question is whether Osypka output and hospital conversion keep that step-up intact after the Robocath close added a French mechanical-robotics burn to an already thin treasury.